— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.
— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.
— Net product sales were $1.28 billion.
— EYLEA net product sales in the US were $1.22 billion.
— Sanofi and Bayer collaboration revenues were $748 million.
— R&D expenses totaled $683 million.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Key takeaways from Kroger’s (KR) Q1 2025 earnings report
The Kroger Co. (NYSE: KR) recently reported mixed results for the first quarter of fiscal 2025, with earnings beating estimates and sales missing. The grocery giant’s stock rose following the
What to expect when McCormick & Company (MKC) reports Q2 2025 earnings results
Shares of McCormick & Company, Incorporated (NYSE: MKC) gained over 1% on Monday. The stock has dropped 7% over the past three months. The condiments maker is slated to report its second
Earnings Preview: Paychex (PAYX) looks set to end FY25 on a strong note
Paychex Inc. (NASDAQ: PAYX) has benefited from the stable labor market and resilient customers, despite inflationary pressures and the challenging economic environment. The company is leveraging its strong fundamentals and
Comments
Comments are closed.